Blueprint Medicines (BPMC) PT Raised to $55 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Wells Fargo analyst Derek Archila raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $55.00 (from $48.00) while maintaining a Equal Weight rating.
You May Also Be Interested In
- Procore Technologies, Inc (PCOR) PT Raised to $90 at BTIG
- ONEOK Inc (OKE) PT Raised to $108 at Argus
- Pfizer (PFE) PT Raised to $40 at Argus
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
